What is Talus Bioscience?
Talus Bioscience is a drug discovery company founded by a world-class team of scientific leaders in proteomics, biochemistry, and machine learning. The company leverages its deep scientific expertise and advanced technological capabilities to identify and develop novel therapeutic candidates. Its focus on interdisciplinary science positions it at the forefront of innovation in the pharmaceutical and biotechnology landscape, aiming to address unmet medical needs through cutting-edge research and development.
How much funding has Talus Bioscience raised?
Talus Bioscience has raised a total of $20.9M across 2 funding rounds:
Unspecified
$9.8M
Angel/Seed
$11.2M
Unspecified (2022): $9.8M, investors not publicly disclosed
Angel/Seed (2024): $11.2M led by WRF Capital, The NFX, and Two Bear Capital
Key Investors in Talus Bioscience
WRF Capital
Washington Research Foundation is a prominent early-stage investor focused on transforming innovative ideas into successful businesses based in Washington. With an annual investment of approximately $5 million, WRF Capital prioritizes startups emerging from local nonprofit research institutions, specializing in life sciences, information technology, and physical sciences.
The NFX
NFX is a venture capital firm that focuses on investing in pre-seed and seed stage startups, aiming to support exceptional founders who are building transformative companies across various sectors. Their investment areas include gaming, generative AI, proptech, space, fintech, marketplaces, and crypto.
Two Bear Capital
Two Bear Capital is an investment firm that focuses on supporting founders with innovative solutions to urgent, complex challenges in the life sciences and technology sectors. The company operates in innovation-driven locations such as Menlo Park, New York, San Diego, Boston, and Whitefish, Montana.
What's next for Talus Bioscience?
With the infusion of $11.2M in recent backing, Talus Bioscience is poised for accelerated development and strategic expansion. This capital injection is expected to fuel further research initiatives, enhance its technological infrastructure, and potentially broaden its therapeutic focus areas. The company's trajectory suggests a move towards later-stage development and clinical trials, positioning it for significant milestones in the competitive drug discovery market. Continued investment in its core scientific competencies will be crucial for translating its innovative discoveries into viable treatments.
See full Talus Bioscience company page
